GlassScriptPhysician profile
Christopher Malsch
NPI 1851356372
$15,083.64
in general payments reported to CMS, 2019-2025
29 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,802 · 2020: $1,039 · 2021: $2,736 · 2022: $963 · 2023: $359 · 2024: $7,596 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,140 · Food and Beverage: $1,382 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,140.00 |
| Food and Beverage | $1,382.06 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $7,219.56 | 2024-2025 | Loreev Xr, Teriparatide |
| Biohaven Pharmaceuticals, INC. | $1,374.08 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $890.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $747.72 | 2019-2021 | |
| Novo Nordisk INC | $731.44 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Kowa Pharmaceuticals America, INC. | $470.62 | 2019-2025 | Seglentis, Zoryve, Livalo |
| Lilly USA, LLC | $433.16 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Amarin Pharma, INC. | $414.14 | 2019-2021 | |
| Abbvie INC. | $401.72 | 2019-2024 | |
| Gilead Sciences, INC. | $385.43 | 2019-2025 | Yeztugo, Descovy |
| Merck Sharp & Dohme LLC | $231.37 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.21 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.67 | 2019-2022 | |
| Axsome Therapeutics, INC. | $209.78 | 2022-2025 | Auvelity, Sunosi |
| Glaxosmithkline, LLC. | $185.97 | 2024-2025 | Arexvy, Trelegy Ellipta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $164.34 | 2019-2021 | |
| Allergan, INC. | $148.98 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $125.12 | 2023-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $112.14 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.00 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.01 | 2019-2021 | |
| Amgen INC. | $52.73 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $48.44 | 2021 | |
| Janssen Pharmaceuticals, INC | $34.37 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $20.93 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.01 | 2020 | |
| Intuity Medical INC | $17.09 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Radius Health, INC. | $15.00 | 2021 | |
| Aytu Biopharma, INC. | $14.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Malsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.